Xcell Therapeutics (373110.KQ)
- Previous Close
3,805.00 - Open
3,805.00 - Bid 3,715.00 x --
- Ask 3,750.00 x --
- Day's Range
3,705.00 - 3,815.00 - 52 Week Range
3,220.00 - 12,900.00 - Volume
45,485 - Avg. Volume
208,017 - Market Cap (intraday)
40.671B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea.
xcell.co.kr/kor/Recent News: 373110.KQ
View MorePerformance Overview: 373110.KQ
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 373110.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 373110.KQ
View MoreValuation Measures
Market Cap
40.67B
Enterprise Value
37.57B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.26
Price/Book (mrq)
4.46
Enterprise Value/Revenue
19.42
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.63%
Return on Equity (ttm)
-165.90%
Revenue (ttm)
1.93B
Net Income Avi to Common (ttm)
-9.54B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
8.8B
Total Debt/Equity (mrq)
62.51%
Levered Free Cash Flow (ttm)
-5.08B